{
    "clinical_study": {
        "@rank": "141327", 
        "acronym": "TRANSFORM", 
        "arm_group": [
            {
                "arm_group_label": "Endoscopic Lung Volume Reduction", 
                "arm_group_type": "Experimental", 
                "description": "Patients are implanted Zephyr EBV"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "No Intervention", 
                "description": "Patients are given Standard of Care treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the clinical outcomes of Endoscopic Lung Volume Reduction using Pulmonx Zephyr\n      Endobronchial Valve (EBV) vs. Standard of Care (SoC) in the treatment of heterogeneous\n      emphysema patients in a controlled trial design setting."
        }, 
        "brief_title": "To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV", 
        "condition": [
            "COPD", 
            "Heterogeneous Emphysema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Emphysema", 
                "Pulmonary Emphysema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Heterogeneous emphysema\n\n          -  15% pred < or = FEV1 < or = 45% pred\n\n          -  TLC > 100% and RV > or = 180%\n\n          -  150 m < or = 6MWT < or = 450 m\n\n          -  No collateral ventilation\n\n        Exclusion Criteria:\n\n          -  Contraindication to bronchoscopy\n\n          -  Active pulmonary infection\n\n          -  History of 2 or more exacerbations with hospitalization over the past 12 months\n\n          -  Known pulmonary hypertension\n\n          -  Prior LVR or LVRS procedure\n\n          -  Pregnant or lactating woman\n\n          -  Hypercapnia\n\n          -  Obstruction reversibility (pre vs post-BD FEV1) > 15%\n\n          -  CV in the target lobe or inconclusive Chartis assessment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022683", 
            "org_study_id": "630-0015/A"
        }, 
        "intervention": {
            "arm_group_label": "Endoscopic Lung Volume Reduction", 
            "description": "Standard Medical Care", 
            "intervention_name": "ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endoscopic lung volume reduction", 
            "Endobronchial valves"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Uppsala", 
                    "country": "Sweden"
                }, 
                "name": "Department of Pulmonary Diseases"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema", 
        "other_outcome": {
            "measure": "Changes in Target Lobar Volume Reduction (TLVR), Residual Volume, EQ-5D summary index, AEs and SAEs, paO2", 
            "safety_issue": "Yes", 
            "time_frame": "Change in TLVR between baseline and 45 days"
        }, 
        "overall_contact": {
            "email": "eliljensten@liljenstenc.com", 
            "last_name": "Elisabeth Liljensten, DDS, PhD", 
            "phone": "0046-723 61 1968"
        }, 
        "overall_official": {
            "affiliation": "Uppsala University Hospital Sweden", 
            "last_name": "Gunnar Hillerdal, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in FEV1", 
            "safety_issue": "No", 
            "time_frame": "Between baseline and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Changes in St George's Respiratory Questionnaire, 6-Min Walk Test, BODE index, mMRC score,", 
            "safety_issue": "No", 
            "time_frame": "Betwenn baseline and 3, 6, 12, 18, and 24 months"
        }, 
        "source": "Pulmonx, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pulmonx, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}